Overview

* Pharvaris ( PHVS ) reports cash and equivalents of €329 mln as of September 30, 2025

* Company progressing with pivotal Phase 3 trials, data expected in 4Q2025 and 2H2026

* Pharvaris ( PHVS ) initiates CREAATE study for AAE-C1INH, expanding clinical focus

Outlook

* Pharvaris ( PHVS ) expects RAPIDe-3 topline data in 4Q2025

* CHAPTER-3 topline data anticipated in 2H2026

* Company initiated CREAATE study for AAE-C1INH treatment

Result Drivers

* R&D - Expenses were €29.8 million for the quarter ended September 30, 2025, compared to €25.8 million for the quarter ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -EUR

0.60

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Pharvaris NV ( PHVS ) is $32.50, about 25.8% above its November 11 closing price of $24.12

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)